Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 78


Pathologic complete response predicts recurrence-free survival more effectively by cancer subset: results from the I-SPY 1 TRIAL--CALGB 150007/150012, ACRIN 6657.

Esserman LJ, Berry DA, DeMichele A, Carey L, Davis SE, Buxton M, Hudis C, Gray JW, Perou C, Yau C, Livasy C, Krontiras H, Montgomery L, Tripathy D, Lehman C, Liu MC, Olopade OI, Rugo HS, Carpenter JT, Dressler L, Chhieng D, Singh B, Mies C, Rabban J, Chen YY, Giri D, van 't Veer L, Hylton N.

J Clin Oncol. 2012 Sep 10;30(26):3242-9. doi: 10.1200/JCO.2011.39.2779. Epub 2012 May 29.


Dinaciclib (SCH 727965), a novel and potent cyclin-dependent kinase inhibitor.

Parry D, Guzi T, Shanahan F, Davis N, Prabhavalkar D, Wiswell D, Seghezzi W, Paruch K, Dwyer MP, Doll R, Nomeir A, Windsor W, Fischmann T, Wang Y, Oft M, Chen T, Kirschmeier P, Lees EM.

Mol Cancer Ther. 2010 Aug;9(8):2344-53. doi: 10.1158/1535-7163.MCT-10-0324. Epub 2010 Jul 27.


Therapeutic potential of a synthetic lethal interaction between the MYC proto-oncogene and inhibition of aurora-B kinase.

Yang D, Liu H, Goga A, Kim S, Yuneva M, Bishop JM.

Proc Natl Acad Sci U S A. 2010 Aug 3;107(31):13836-41. doi: 10.1073/pnas.1008366107. Epub 2010 Jul 19.


Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and advanced breast cancer: a proof-of-concept trial.

Tutt A, Robson M, Garber JE, Domchek SM, Audeh MW, Weitzel JN, Friedlander M, Arun B, Loman N, Schmutzler RK, Wardley A, Mitchell G, Earl H, Wickens M, Carmichael J.

Lancet. 2010 Jul 24;376(9737):235-44. doi: 10.1016/S0140-6736(10)60892-6. Epub 2010 Jul 6.


Altered subcellular localization of c-Myc protein identifies aggressive B-cell lymphomas harboring a c-MYC translocation.

Ruzinova MB, Caron T, Rodig SJ.

Am J Surg Pathol. 2010 Jun;34(6):882-91. doi: 10.1097/PAS.0b013e3181db83af.


Adaptive trials receive boost.

Jones D.

Nat Rev Drug Discov. 2010 May;9(5):345-8. doi: 10.1038/nrd3174. Epub 2010 Apr 23. No abstract available.


A pathway-based classification of human breast cancer.

Gatza ML, Lucas JE, Barry WT, Kim JW, Wang Q, Crawford MD, Datto MB, Kelley M, Mathey-Prevot B, Potti A, Nevins JR.

Proc Natl Acad Sci U S A. 2010 Apr 13;107(15):6994-9. doi: 10.1073/pnas.0912708107. Epub 2010 Mar 24.


Breast cancer subtypes and the risk of local and regional relapse.

Voduc KD, Cheang MC, Tyldesley S, Gelmon K, Nielsen TO, Kennecke H.

J Clin Oncol. 2010 Apr 1;28(10):1684-91. doi: 10.1200/JCO.2009.24.9284. Epub 2010 Mar 1.


Exploiting synthetic lethal interactions for targeted cancer therapy.

Reinhardt HC, Jiang H, Hemann MT, Yaffe MB.

Cell Cycle. 2009 Oct 1;8(19):3112-9. Review.


A core MYC gene expression signature is prominent in basal-like breast cancer but only partially overlaps the core serum response.

Chandriani S, Frengen E, Cowling VH, Pendergrass SA, Perou CM, Whitfield ML, Cole MD.

PLoS One. 2009 Aug 19;4(8):e6693. doi: 10.1371/journal.pone.0006693.


Mimicking the BH3 domain to kill cancer cells.

Ni Chonghaile T, Letai A.

Oncogene. 2008 Dec;27 Suppl 1:S149-57. doi: 10.1038/onc.2009.52. Review.


Inhibition of poly(ADP-ribose) polymerase in tumors from BRCA mutation carriers.

Fong PC, Boss DS, Yap TA, Tutt A, Wu P, Mergui-Roelvink M, Mortimer P, Swaisland H, Lau A, O'Connor MJ, Ashworth A, Carmichael J, Kaye SB, Schellens JH, de Bono JS.

N Engl J Med. 2009 Jul 9;361(2):123-34. doi: 10.1056/NEJMoa0900212. Epub 2009 Jun 24.


Inactivation of CDK2 is synthetically lethal to MYCN over-expressing cancer cells.

Molenaar JJ, Ebus ME, Geerts D, Koster J, Lamers F, Valentijn LJ, Westerhout EM, Versteeg R, Caron HN.

Proc Natl Acad Sci U S A. 2009 Aug 4;106(31):12968-73. doi: 10.1073/pnas.0901418106. Epub 2009 Jun 12.


I-SPY 2: an adaptive breast cancer trial design in the setting of neoadjuvant chemotherapy.

Barker AD, Sigman CC, Kelloff GJ, Hylton NM, Berry DA, Esserman LJ.

Clin Pharmacol Ther. 2009 Jul;86(1):97-100. doi: 10.1038/clpt.2009.68. Epub 2009 May 13.


Ki67 index, HER2 status, and prognosis of patients with luminal B breast cancer.

Cheang MC, Chia SK, Voduc D, Gao D, Leung S, Snider J, Watson M, Davies S, Bernard PS, Parker JS, Perou CM, Ellis MJ, Nielsen TO.

J Natl Cancer Inst. 2009 May 20;101(10):736-50. doi: 10.1093/jnci/djp082. Epub 2009 May 12.


Development of cell-cycle inhibitors for cancer therapy.

Dickson MA, Schwartz GK.

Curr Oncol. 2009 Mar;16(2):36-43.


Androgen receptor levels and association with PIK3CA mutations and prognosis in breast cancer.

Gonzalez-Angulo AM, Stemke-Hale K, Palla SL, Carey M, Agarwal R, Meric-Berstam F, Traina TA, Hudis C, Hortobagyi GN, Gerald WL, Mills GB, Hennessy BT.

Clin Cancer Res. 2009 Apr 1;15(7):2472-8. doi: 10.1158/1078-0432.CCR-08-1763. Epub 2009 Mar 10.


Meta-analysis and gene set enrichment relative to er status reveal elevated activity of MYC and E2F in the "basal" breast cancer subgroup.

Alles MC, Gardiner-Garden M, Nott DJ, Wang Y, Foekens JA, Sutherland RL, Musgrove EA, Ormandy CJ.

PLoS One. 2009;4(3):e4710. doi: 10.1371/journal.pone.0004710. Epub 2009 Mar 9.


Triple-negative breast cancer: risk factors to potential targets.

Schneider BP, Winer EP, Foulkes WD, Garber J, Perou CM, Richardson A, Sledge GW, Carey LA.

Clin Cancer Res. 2008 Dec 15;14(24):8010-8. doi: 10.1158/1078-0432.CCR-08-1208. Review.


Reflecting on 25 years with MYC.

Meyer N, Penn LZ.

Nat Rev Cancer. 2008 Dec;8(12):976-90. doi: 10.1038/nrc2231. Review.

Items per page

Supplemental Content

Write to the Help Desk